A somewhat gentle introduction to differential graded commutative algebra

Differential graded (DG) commutative algebra provides powerful techniques for proving theorems about modules over commutative rings. These notes are a somewhat colloquial introduction to these techniques. In order to provide some motivation for commutative algebraists who are wondering about the benefits of learning and using these techniques, we present them in the context of a recent result of Nasseh and Sather-Wagstaff. These notes were used for the course "Differential Graded Commutative Algebra" that was part of the Workshop on Connections Between Algebra and Geometry held at the University of Regina, May 29--June 1, 2012.Comment: 78 page

Secukinumab in the treatment of psoriasis: patient selection and perspectives.

Secukinumab is a human monoclonal antibody targeting IL-17A that has been approved for three indications: moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. In Phase III clinical trials for each of these three indications, secukinumab has proven to be both highly efficacious and well-tolerated. However, several biologic medications are currently approved for the treatment of moderate-to-severe plaque psoriasis, and many demonstrate excellent efficacy and safety. Due to this wide selection, it is often unclear how to choose biologics for specific patients. Important considerations in biologic selection include clinical efficacy, safety, cost, convenience, onset of action, and management of comorbid disease. This article aims to outline the key considerations in patient selection for the treatment of plaque psoriasis with secukinumab

Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date.

Plaque psoriasis is an immune-mediated skin disease that affects roughly 3% of adults in the United States. Advances over the past 20 years in understanding the immune-mediated pathophysiology of psoriasis have led to the development of targeted biologic therapies for this condition. Currently, biologic medications approved for the treatment of plaque psoriasis include tumor necrosis factor α inhibitors, interleukin (IL)-17 or IL-17 receptor inhibitors, IL-12/23 inhibitors, and IL-23 inhibitors. Tildrakizumab-asmn is a monoclonal antibody that targets the p19 subunit of IL-23 and is approved for use in adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. This article reviews the current pharmacologic, efficacy, and safety data on tildrakizumab-asmn

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives.

Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of psoriatic arthritis (PsA). It provides an alternative option for patients who have had an inadequate response and tolerance to other disease modifying antirheumatic drugs (DMARDs). It has demonstrated comparable efficacy to biologics, is effective in the management of treatment resistant disease, and is reported to improve enthesitis, dactylitis, and radiographic progression. Tofacitinib is also associated with an increased risk of serious infections, malignancy, and laboratory abnormalities. There is currently a large armamentarium of therapies for psoriatic arthritis, and choosing among treatments can be challenging. Due to this wide selection, a thorough assessment of psoriatic disease phenotype, patient preference, disease presentation, and comorbidities is critical. This review addresses key considerations in patient selection for the treatment of PsA with tofacitinib

Acrodermatitis continua of Hallopeau: clinical perspectives.

Acrodermatitis continua of Hallopeau (ACH) is a rare, sterile pustular eruption of one or more digits. The condition presents with tender pustules and underlying erythema on the tip of a digit, more frequently arising on a finger than a toe. As far as classification, ACH is considered a localized form of pustular psoriasis. The eruption typically occurs after local trauma or infection, but such a history is not always present and various other etiologies have been described including infectious, neural, inflammatory, and genetic causes. The natural progression of ACH is chronic and progressive, often resulting in irreversible complications such as onychodystrophy that can result in anonychia, as well as osteitis that can result in osteolysis of the distal phalanges. Because of the rarity of ACH, there have been no randomized controlled studies to evaluate therapies, resulting in an absence of standardized treatment guidelines. In clinical practice, a wide variety of treatments have been attempted, with outcomes ranging from recalcitrance to complete resolution. In recent years, the introduction of biologics has provided a new class of therapy that has revolutionized the treatment of ACH. Specifically, rapid and sustained responses have been reported with the use of anti-tumor necrosis factor agents like infliximab, adalimumab, and etanercept; IL-17 inhibitors like secukinumab; IL-12/23 inhibitors like ustekinumab; and IL-1 inhibitors like anakinra. Nevertheless, there remains a considerable need for more research into treatment for the benefit of individual patients with ACH as well as for the clinical knowledge gained by such efforts. The purpose of this review is to provide a comprehensive overview of the key features of ACH as well as a discussion of clinical management strategies for this unique and debilitating condition

”CyberWorld” as a Theme for a University-wide First-year Common Course

Nowadays we all live in a cyber world and use the internet for emailing, banking, streaming video, shopping, reading news, or other activities. Given all the time people spend online, it is important that all students (regardless of their major) learn some basics about living in a cyber world, e.g., strategies for online safety, impact of artificial intelligence, digital forensics or ancestry.com. To facilitate students from many majors to learn about important issues related to the internet, eight faculty from a variety of disciplines at the University of New Haven integrated the theme of Cyber World into our team-taught, first-year experience course, also referred to as the “Common Course.” The Common Course’s primary purpose is to enable students to develop evidence-based arguments and to challenge their own and others’ assumptions in relation to that evidence. Each Common Course class focuses on a broad topic (e.g., Justice, Happiness, or Identity) that instructors use as a touch point to facilitate critical thinking. In Cyber World, however, the topic is given stronger focus, and all students in the class are expected to come away with specific cyber-related knowledge. A special challenge is that the majority of the 160 students are from non-STEM majors. Given the varied background of students, this course covers a variety of topics such as sharing DNA with ancestry.com, protecting against identity theft, detecting fake news, and oversharing personal information. The course is taught by eight faculty members from four different colleges having expertise in a variety of disciplines. An important side effect of this faculty diversity is that interdisciplinary collaborations among faculty are promoted. Our paper has three significant contributions: (1) We present the eight topics related to living in a cyber world that we chose for this course, including our rationale for why they are appropriate and relevant; (2) We summarize how we integrated the Cyber World topics into the structure of the Common Course, which includes a discussion of the challenges we faced; and (3) We summarize some initial results on how students perceived their experience as well as how they performed compared to other common course sections / topics